UNSPSC 51351527: Pregnenolone succinate

This classification denotes a therapeutic progestin with the molecular structure C25H36O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 6LN4W6JJK6 chemically known as pregn-5-en-20-one, 3-(3-carboxy-1-oxopropoxy)-, (3.beta.), but more commonly known as pregnenolone succinate, which bears US NIH Compound Identifier 20728. European Medicines Agency schedules Pregnenolone succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15007MIG.

UNSPSC 51351527 Pregnenolone succinate is a Commodity code covering a single pharmaceutical active ingredient, but recent state and local procurement activity under this code shows minimal specificity — the primary documented opportunity treats pregnenolone succinate as one product line within a much broader generic multi-source pharmaceutical and OTC product solicitation. State and local governments use this code when acquiring pregnenolone succinate as part of larger formulary or generic drug purchasing programs for public health facilities, correctional institutions, and related medicinal-supply operations. The soliciting bodies are typically state departments of health, corrections, or administration; county public health agencies; and city or regional hospital systems. When pregnenolone succinate appears in solicitations, it is usually bundled with dozens or hundreds of other generic pharmaceuticals rather than procured standalone.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the primary recent opportunity — a Request for Proposal posted January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. The RFP requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, hold $5 million in commercial general liability insurance, and accept a 3 percent administrative fee. Evaluation weights pricing competitiveness at 75 percent, with the remainder split among fixed pricing, administrative compliance, EDI capability, and fee acceptance. The contract term is two years for new responders with optional extensions, effective July 1, 2026. No other state or local pregnenolone succinate–specific solicitations appear in recent records; activity under this code is sparse and appears limited to cooperative purchasing vehicles serving multiple jurisdictions.